Takis Athanasopoulos

List of Publications by Year
in descending order

34 papers	1,313 citations	430874 18 h-index	414414 32 g-index
34 all docs	34 docs citations	34 times ranked	2136 citing authors

#	Article	IF	Citations
1	The role of small molecules in cell and gene therapy. RSC Medicinal Chemistry, 2021, 12, 330-352.	3.9	3
2	Success Stories and Challenges Ahead in Hematopoietic Stem Cell Gene Therapy: Hemoglobinopathies as Disease Models. Human Gene Therapy, 2021, 32, 1120-1137.	2.7	3
3	The Landscape of Early Clinical Gene Therapies outside of Oncology. Molecular Therapy, 2019, 27, 1706-1717.	8.2	18
4	Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nature Communications, 2017, 8, 16105.	12.8	175
5	A Tribute to George Stamatoyannopoulos. Human Gene Therapy, 2016, 27, 280-286.	2.7	0
6	piggyBactransposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucleic Acids Research, 2016, 44, 744-760.	14.5	25
7	Abnormal splicing switch of DMDâ€™s penultimate exon compromises muscle fibre maintenance in myotonic dystrophy. Nature Communications, 2015, 6, 7205.	12.8	76
8	Genome-wide Computational Analysis Reveals Cardiomyocyte-specific Transcriptional Cis-regulatory Motifs That Enable Efficient Cardiac Gene Therapy. Molecular Therapy, 2015, 23, 43-52.	8.2	36
9	Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD). Current Gene Therapy, 2015, 15, 395-415.	2.0	17
10	Fusion of Ubiquitin to HIV Gag Impairs Human Monocyte-Derived Dendritic Cell Maturation and Reduces Ability to Induce Gag T Cell Responses. PLoS ONE, 2014, 9, e88327.	2.5	6
11	Triple Trans-Splicing Adeno-Associated Virus Vectors Capable of Transferring the Coding Sequence for Full-Length Dystrophin Protein into Dystrophic Mice. Human Gene Therapy, 2014, 25, 98-108.	2.7	80
12	Langerin negative dendritic cells promote potent CD8 ⁺ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3041-3046.	7.1	82
13	Highly potent delivery method of gp160 envelope vaccine combining lentivirus-like particles and DNA electrotransfer. Journal of Controlled Release, 2012, 159, 376-383.	9.9	9
14	Fragmentation of SIV-gag Vaccine Induces Broader T Cell Responses. PLoS ONE, 2012, 7, e48038.	2.5	5
15	Delivery of AAV2/9-Microdystrophin Genes Incorporating Helix 1 of the Coiled-Coil Motif in the C-Terminal Domain of Dystrophin Improves Muscle Pathology and Restores the Level of Î±1-Syntrophin and Î±-Dystrobrevin in Skeletal Muscles of mdx Mice. Human Gene Therapy, 2011, 22, 1379-1388.	2.7	52
16	Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle. Metabolism: Clinical and Experimental, 2011, 60, 491-498.	3.4	5
17	Longâ€term functional adenoâ€associated virusâ€microdystrophin expression in the dystrophic CXMDj dog. Journal of Gene Medicine, 2011, 13, 497-506.	2.8	57
18	Î²â€catenin as a potential key target for tumor suppression. International Journal of Cancer, 2011, 129, 1541-1551.	5.1	93

#	Article	IF	Citations
19	Transcription Factor Rational Design Improves Directed Differentiation of Human Mesenchymal Stem Cells Into Skeletal Myocytes. Molecular Therapy, 2011, 19, 1331-1341.	8.2	29
20	Codon Optimization of the Microdystrophin Gene for Duchenne Muscular Dystrophy Gene Therapy. Methods in Molecular Biology, 2011, 709, 21-37.	0.9	16
21	Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization. BMC Genomics, 2010, 11, 345.	2.8	26
22	Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19940-19945.	7.1	136
23	Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opinion on Biological Therapy, 2009, 9, 849-866.	3.1	44
24	Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice. Atherosclerosis, 2009, 204, 121-126.	0.8	13
25	Activity of different vaccine-associated promoter elements in human dendritic cells. Immunology Letters, 2008, 115, 117-125.	2.5	5
26	Human Apolipoprotein E Expression from Mouse Skeletal Muscle by Electrotransfer of Nonviral DNA (Plasmid) and Pseudotyped Recombinant Adeno-Associated Virus (AAV2/7). Human Gene Therapy, 2008, 19, 569-578.	2.7	14
27	Codon and mRNA Sequence Optimization of Microdystrophin Transgenes Improves Expression and Physiological Outcome in Dystrophic mdx Mice Following AAV2/8 Gene Transfer. Molecular Therapy, 2008, 16, 1825-1832.	8.2	107
28	RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. Human Molecular Genetics, 2008, 17, 2622-2632.	2.9	40
29	907. Development of Recombinant Novel Adeno-Associated Viral (rAAV) Vectors Encoding Optimised Microdystrophin cDNAs for Duchenne Muscular Dystrophy (DMD). Molecular Therapy, 2006, 13, S349-S350.	8.2	0
30	Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Therapy, 2002, 9, 21-29.	4.5	29
31	Post-mitotic, differentiated myotubes efficiently produce retroviral vector from hybrid adeno-retrovirus templates. Gene Therapy, 2001, 8, 1580-1586.	4.5	7
32	Cell-derived Apolipoprotein E (ApoE) Particles Inhibit Vascular Cell Adhesion Molecule-1 (VCAM-1) Expression in Human Endothelial Cells. Journal of Biological Chemistry, 2001, 276, 46011-46016.	3.4	81
33	Intramuscular injection of a plasmid vector expressing human apolipoprotein E limits progression of xanthoma and aortic atheroma in apoE-deficient mice. Human Molecular Genetics, 2000, 9, 2545-2551.	2.9	23
34	Gene therapy for atherosclerosis: A comparative study of adeno-associated virus (AAV) and conventional plasmid vectors encoding human apolipopoprotein E (apoE) cDNAs. Atherosclerosis, 1999, 144, 93-94.	0.8	1